| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Salicyluric acid demonstrates inhibition of integrase activity in vitro, showing 28.9% and 33.3% inhibition in the 3'-processing method and 25.0% and 33.3% inhibition in the strand transfer method. It exhibits anti-inflammatory and antioxidant effects. It is a uremic toxin and may contribute to kidney disease pathophysiology.
|
|---|---|
| ln Vitro |
In vitro, salicyluric acid inhibits integrase activity. It exhibits anti-inflammatory and antioxidant effects. The compound's biological activities are related to its role as a salicylic acid metabolite. It may modulate COX-1 enzymatic activity to decrease the formation of pro-inflammatory prostaglandins. Further in vitro studies are needed to fully characterize its activity.
|
| ln Vivo |
In vivo, salicyluric acid is a major metabolite of salicylic acid, accounting for a significant portion of salicylate excretion. It is a uremic toxin that accumulates in patients with kidney disease. The compound may contribute to the anti-inflammatory effects of salicylates. Its antioxidant properties may provide protective effects against oxidative stress in vivo. It is an endogenous metabolite.
|
| Enzyme Assay |
In vitro enzyme assays for integrase inhibition involve incubating the enzyme with salicyluric acid (1-100 µM) and a DNA substrate in buffer at 37°C. 3'-processing and strand transfer activities are measured by gel electrophoresis or fluorescence-based assays. For COX-1 inhibition, the enzyme is incubated with arachidonic acid and the compound, and prostaglandin production is measured by ELISA. Anti-inflammatory activity is assessed by measuring cytokine production in stimulated cells.
|
| Cell Assay |
For in vitro cell assays, cells are cultured in medium supplemented with salicyluric acid at concentrations of 0.1-10 mM. Cell viability is assessed by MTT assay. Anti-inflammatory effects are evaluated by measuring pro-inflammatory cytokine levels (TNF-α, IL-6) in LPS-stimulated cells using ELISA. Antioxidant activity is assessed by measuring ROS levels and glutathione content. Integrase inhibition can be studied in cell-based assays using HIV-1 integrase.
|
| Animal Protocol |
For in vivo animal studies, salicyluric acid is administered to rodents via oral gavage or intravenous injection at doses of 10-100 mg/kg. Blood and urine samples are collected for pharmacokinetic analysis. The compound is quantified by HPLC or LC-MS/MS. In kidney disease models, uremic toxin levels are measured to assess accumulation. Anti-inflammatory effects are evaluated by measuring inflammatory markers in serum and tissues.
|
| ADME/Pharmacokinetics |
Salicyluric acid has a molecular weight of 195.17. It is soluble in water and organic solvents. The compound is stable under standard storage conditions. It is absorbed and metabolized through glycine conjugation pathways. As a uremic toxin, it accumulates in patients with renal impairment. The compound is an N-acylglycine and a secondary amide.
|
| Toxicity/Toxicokinetics |
Salicyluric acid is for research use only. No specific toxicity data are available in the search results. As a uremic toxin, it may contribute to the pathophysiology of kidney disease at elevated concentrations. The compound is a metabolite of salicylic acid and shares some of its pharmacological properties. Standard safety precautions should be followed when handling.
|
| Additional Infomation |
Salicyluric acid is an N-acylglycine with a 2-hydroxybenzoyl acyl group. It is a uremic toxin and a xenobiotic metabolite in humans. It is an N-acylglycine and a secondary amide. Its function is related to glycine. It is the conjugate acid of salicylourate. Salicyluric acid has been reported to exist in Trypanosoma kunillae and Trypanosoma bryonis, and relevant data are available. Salicylourate is a metabolite found or produced in Saccharomyces cerevisiae.
Salicyluric acid (CAS# 487-54-7) is an endogenous metabolite and research reagent used primarily in studies of salicylate metabolism, uremic toxicity, and inflammation. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is used as a biomarker for salicylate exposure and in studies of kidney disease. Its anti-inflammatory and antioxidant activities are of research interest. |
| Molecular Formula |
C9H9NO4
|
|---|---|
| Molecular Weight |
195.17
|
| Exact Mass |
195.053
|
| CAS # |
487-54-7
|
| Related CAS # |
Salicyluric acid-13C2,15N;1286521-95-6
|
| PubChem CID |
10253
|
| Appearance |
White to off-white solid powder
|
| Density |
1.401 g/cm3
|
| Boiling Point |
489.8ºC at 760 mmHg
|
| Melting Point |
168 °C
|
| Flash Point |
250ºC
|
| Vapour Pressure |
2.08E-10mmHg at 25°C
|
| LogP |
0.597
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
229
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C(=C1)C(=O)NCC(=O)O)O
|
| InChi Key |
ONJSZLXSECQROL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H9NO4/c11-7-4-2-1-3-6(7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)
|
| Chemical Name |
2-[(2-hydroxybenzoyl)amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (512.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1237 mL | 25.6187 mL | 51.2374 mL | |
| 5 mM | 1.0247 mL | 5.1237 mL | 10.2475 mL | |
| 10 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
